West Pharmaceutical Services, Inc. - 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2010, filed on May 6, 2010. West Pharmaceutical Services, Inc. is a global manufacturer of pharmaceutical packaging and delivery systems. Effective January 1, 2010, the company reorganized its operations into two reportable segments: Packaging Systems (stoppers, seals, closures) and Delivery Systems (custom contract manufacturing, safety systems). The company is a large accelerated filer with 33,258,074 shares of common stock outstanding as of April 30, 2010.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2010 | Q1 2009 |
|---|---|---|
| Net Sales | $274.7 | $242.4 |
| Gross Profit | $82.2 | $69.3 |
| Gross Margin | 29.9% | 28.6% |
| Operating Profit | $28.9 | $21.2 |
| Net Income | $19.8 | $15.4 |
| Diluted EPS | $0.57 | $0.46 |
| Operating Cash Flow | $11.5 | $(3.3) |
| Cash & Equivalents (End of Period) | $65.9 | $62.7 |
| Total Debt | $369.4 | $379.6 |
| Working Capital | $221.1 | $226.1 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 13.3% year-over-year. Excluding favorable foreign currency effects ($9.8 million), sales grew 9.3% due to higher volume, favorable product mix, and the impact of the July 2009 Plastef acquisition.
- Profitability: Operating profit rose 36% to $28.9 million, driven by improved gross margins in the Packaging Systems segment (up 2.8 percentage points) and better plant utilization.
- Segment Performance: Packaging Systems operating profit increased $10.9 million to $39.8 million. Delivery Systems operating profit declined $1.9 million to $1.2 million due to higher SG&A and R&D costs associated with the new segment structure and acquisition integration.
- Cash Flow: Operating cash flow improved significantly to $11.5 million from a negative $3.3 million in Q1 2009, largely due to higher net earnings and the absence of a $10.0 million voluntary pension contribution made in the prior year.
- Debt Reclassification: $20.6 million of debt under the revolving credit facility was reclassified from long-term to current liabilities as the facility matures in February 2011.
Guidance, Outlook, and Risks
- Capital Expenditures: Full-year 2010 capital spending is expected to be between $115.0 million and $130.0 million, compared to $104.9 million in 2009.
- Restructuring: The company expects to incur an additional $1.0 million to $1.5 million in restructuring costs for the remainder of 2010, primarily for fixed asset relocation in the Delivery Systems segment.
- Tax Outlook: The estimated annual effective tax rate for 2010 is 24.9%, slightly higher than 2009 due to the expiration of a U.S. R&D tax credit, pending legislative extension.
- Liquidity: The company maintains ample liquidity with $177.3 million available under its $200.0 million revolving credit facility. Management is negotiating a replacement facility to mature in February 2011.
- Risks: Key risks include dependence on third-party suppliers (including single-source supplier Daikyo Seiko), raw material price escalation (petroleum-based), foreign currency fluctuations, and the impact of healthcare reform legislation.
Investor Verification Checklist
- Credit Facility Refinancing: Verify the status of negotiations for the replacement revolving credit facility maturing in February 2011 and expected interest rate terms.
- Restructuring Costs: Monitor the actual execution of the remaining $1.0–$1.5 million in restructuring charges and the timeline for Delivery Systems consolidation.
- Foreign Currency Impact: Assess the sensitivity of future earnings to exchange rate fluctuations, particularly the Euro and Yen, given the significant portion of international sales.
- Inventory Levels: Review the increase in inventory ($15.6 million quarter-over-quarter) to ensure it aligns with order backlogs and does not signal future write-downs.
- Plastef Integration: Evaluate the performance of the acquired Plastef assets within the Delivery Systems segment to confirm the realization of projected synergies.